StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BTMD$2.18+0.00%
Fair $2.18+0.0%

BTMD

biote Corp.

Healthcare / Medical Care FacilitiesNasdaqGM

$2.18

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $2.18Fund rank 34/100 · Data gapFallback financials|
SA 28/D
F-Score: 7/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 31% · confianza 25%

FCF escenarios

weak_data · normalized FCF $30.2M · quality 66.0/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 52/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

28/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 6Warnings: 1unknown: 6
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -46.2%, below the 5% threshold
Thesis & Journal · BTMDLocal privado en este navegador · biote Corp.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$81M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-46.2%

↓

Gross Margin

N/A

•

Debt/Equity

-1.64

↓
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2020–2025 · 5 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

15.7%

FCF / Net income

1.12x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $192.2M · net income $27.0M · FCF $30.2M

2020-FY → 2025-FY

Gross margin

—— pts

Operating margin

18.5%— pts

Net margin

14.1%— pts

FCF margin

15.7%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
Income Statement
Revenue$192.2M$192.2M$197.2M$185.4M$165.0M$139.4M—
Net Income$27.0M$27.0M$3.2M$3.3M$-969000.00$11.1M—
EBITDA$39.2M$39.2M$35.2M$31.7M$-58.5M$36.0M—
EPS0.740.740.090.13-0.12——
Operating Margin18.5%18.5%16.0%15.5%-36.8%24.8%—
Net Margin14.1%14.1%1.6%1.8%-0.6%8.0%—
Balance Sheet
Debt/Equity-1.64-1.64-0.96-3.63-2.527.75—
Cash Flow
Free Cash Flow$30.2M$30.2M$38.8M$26.5M$-9.5M$32.3M—
Returns
ROE-46.2%-46.2%-3.0%-11.3%2.2%269.4%—
Growth & Yield
Revenue Growth-2.5%-2.5%6.4%12.4%18.3%——
EPS Growth722.2%722.2%-30.8%208.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-36.1%

fácil

EPS terminal req.

$0.19

Spread vs growth

758.3%

5Y implied EPS CAGR

-20.6%

fácil

EPS terminal req.

$0.23

Spread vs growth

742.8%

10Y implied EPS CAGR

-6.5%

fácil

EPS terminal req.

$0.38

Spread vs growth

728.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.